Utility of octreoide as second line treatment in concurrent chemoradiation induced diarrhea: Preliminary results in 20 patients;Eşzamanli kemoradyoterapiye baǧli diyarede i̇kinci basamak tedavide oktreotid'in yeri: 20 Hastada ön sonuçlar

THOD - Turk Hematoloji-Onkoloji Dergisi

Volumn 14, Issue 2, 2004, Pages 61-67

  Topkan, Erkan ^a,c   Selek, Uǧur ^b  

^a INONU UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Chemotherapy; Diarrhea; Octreotid; Radiotherapy

Indexed keywords

ELECTROLYTE; FLUOROURACIL; LOPERAMIDE; OCTREOTIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIATION INDUCED DIARRHEA; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; MALE; PARENTERAL NUTRITION; RECTUM CARCINOMA; TURKEY (REPUBLIC);

EID: 3142746815     PISSN: 13018825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kinsella TJ, Bloomer WD. Tolerance of the intestine to radiation therapy. Surg Gynecol Obstet 1980;151:273-284.
2. Wadler S, Benson AB, 3rd, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16:3169-3178.
3. Miller RC, Martenson JA, Sargent DJ, et al. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys 1998;41:593-598.
4. Girinsky T, Rey A, Roche B, et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27:1051-1056.
5. Sthal KS, van Bewer W, Janssen P, et al. Receptor activity and pharmacological potency of a series of narcotic analgesic, antidiarrheal and neurological drugs. Eur J Pharmacol 1977;46:199-205.
6. Mercadante S. Diarrhea in terminally ill patients: pathophysiology and treatment. J Pain Symptom Manage 1995;10:298-309.
7. Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 1998;55:1573-1580.
8. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986;315:663-666.
9. O'Dorisio TM, Gaginella TS, Mekhjian HS, et al. Somatostatin and analogues in the treatment of VIPoma. Ann N Y Acad Sci 1988;527:528-535.
10. Simon DM, Cello JP, Valenzuela J, et al. Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995;108:1753-1760.
11. Maton PN, O'Dorisio TM, Howe BA, et al. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985;312:17-21.
12. Cooper JC, Williams NS, King RF, et al. Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea. Br J Surg 1986;73:128-131.
13. Baillie-Johnson HR. Octreotide in the management of treatment-related diarrhoea. Anticancer Drugs 1996;7 Suppl 1:11-15.
14. Crouch MA, Restino MS, Cruz JM, et al. Octreotide acetate in refractory bone marrow transplant-associated diarrhea. Ann Pharmacother 1996;30:331-336.
15. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993;11:148-151.
16. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993;4:443-445.
17. Goumas P, Naxakis S, Christopoulou A, et al. Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea. Oncologist 1998;3:50-53.
18. Morris JB, Guerrero NH, Furth EE, et al. Somatostatin attenuates ischemic intestinal injury. Am J Surg 1993;165:676-680.
19. Guan D, Maouyo D, Sarfati P, et al. Effects of SMS 201-995 on basal and stimulated pancreatic secretion in rats. Endocrinology 1990;127:298-304.
20. Yavuz MN, Yavuz AA, Aydin F, et al. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys 2002;54:195-202.
21. Trier JS, Browning TH. Morphologic response of the mucosa of human small intestine to x-ray exposure. J Clin Invest 1966;45:194-204.
22. Nussbaum ML, Campana TJ, Weese JL. Radiation-induced intestinal injury. Clin Plast Surg 1993;20:573-580.
23. Gallagher MJ, Brereton HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986;12:1565-1573.
24. de Roy van Zuidewijn DB, Schillings PH, Wobbes T, et al. Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 1992;56:96-107.
25. Rubin P. The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys 1984;10:5-34.
26. Sher ME, Bauer J. Radiation-induced enteropathy. Am J Gastroenterol 1990;85:121-128.
27. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996;334:246-254.
28. Dharmsathaphorn K, Binder HJ, Dobbins JW. Somatostatin stimulates sodium and chloride absorption in the rabbit ileum. Gastroenterology 1980;78:1559-1565.
29. Lembcke B, Creutzfeldt W, Schleser S, et al. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36:108-124.
30. Fuessl HS, Carolan G, Williams G, et al. Effect of a long-acting somatostatin analogue (SMS 201-995) on postprandial gastric emptying of 99mTc-tin colloid and mouth-to-caecum transit time in man. Digestion 1987;36:101-107.
31. Wang J, Zheng H, Sung CC, et al. The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 1999;45:1289-1296.
32. Warhurst G, Turnberg LA, Higgs NB, et al. Multiple G-protein-dependent pathways mediate the antisecretory effects of somatostatin and clonidine in the HT29-19A colonic cell line. J Clin Invest 1993;92:603-611.
33. Ajani JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. Eur J Cancer 1993;29A:2332-2333.
34. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, et al. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy - induced diarrhea in patients with colorectal carcinoma. Cancer 1993;72:1543-1546.